An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci173371 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Jin Young Lee und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase Inhibitor p16, Fibroblasts, Cellular Senescence, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The appearance of senescent cells in age-related diseases has spurred the search for compounds that can target senescent cells in tissues, termed senolytics. However, a major caveat with current senolytic screens is the use of cell lines as targets where senescence is induced in vitro, which does not necessarily reflect the identity and function of pathogenic senescent cells in vivo. Here, we developed a new pipeline leveraging a fluorescent murine reporter that allows for isolation and quantification of p16 Ink4a+ cells in diseased tissues. By high-throughput screening in vitro, precision-cut lung slice (PCLS) screening ex vivo, and phenotypic screening in vivo, we identified a HSP90 inhibitor, XL888, as a potent senolytic in tissue fibrosis. XL888 treatment eliminated pathogenic p16 Ink4a+ fibroblasts in a murine model of lung fibrosis and reduced fibrotic burden. Finally, XL888 preferentially targeted p16 INK4a-hi human lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis (IPF), and reduced p16 INK4a+ fibroblasts from IPF PCLS ex vivo. This study provides proof of concept for a platform where p16 INK4a+ cells are directly isolated from diseased tissues to identify compounds with in vivo and ex vivo efficacy in mice and humans, respectively, and provides a senolytic screening platform for other age-related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep.
- Small Molecule Discovery Center, and.
- Bakar Aging Research Institute, UCSF, San Francisco, California, USA.
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- National Institutes of Health
Zitieren
APA
Lee, J. Y., Reyes, N. S., Ravishankar, S., Zhou, M., Krasilnikov, M., Ringler, C., Pohan, G., Wilson, C., Ang, K. K., Wolters, P. J., Tsukui, T., Sheppard, D., Arkin, M. R., & Peng, T. (2024). An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis. Journal of Clinical Investigation. https://doi.org/10.1172/jci173371
Vancouver
Lee JY, Reyes NS, Ravishankar S, Zhou M, Krasilnikov M, Ringler C, et al. An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis. Journal of Clinical Investigation. 2024. doi:10.1172/jci173371
BibTeX
@article{Lee2024,
author = {Lee, Jin Young and Reyes, Nabora S and Ravishankar, Supriya and Zhou, Minqi and Krasilnikov, Maria and Ringler, Christian and Pohan, Grace and Wilson, Chris and Ang, Kenny Kean-Hooi and Wolters, Paul J and Tsukui, Tatsuya and Sheppard, Dean and Arkin, Michelle R and Peng, Tien},
title = {An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci173371}
}
EUVIMED